TY - JOUR
T1 - Healthcare resource use and indirect costs associated with migraine in Italy
T2 - results from the My Migraine Voice survey
AU - Martelletti, Paolo
AU - Schwedt, Todd J.
AU - Vo, Pamela
AU - Ritrovato, Daniela
AU - Reilly, Margaret C.
AU - Naclerio, Mariantonietta
AU - Ranjan, Pallavi
AU - Kleebach, Joern
AU - Joshi, Parth
N1 - Funding Information:
Within the prior 24 months, TS has received compensation for serving as a consultant or on an advisory board from Alder, Allergan, Amgen, Biohaven, Click Therapeutics, Eli Lilly, Equinox, Lundbeck, Novartis, Weber and Weber, and XoC. He has received research support from the American Migraine Foundation, Amgen, Henry Jackson Foundation, National Institutes of Health, Patient-Centered Outcomes Research Institute, and the United States Department of Defense. He has received royalties from UpToDate. He holds stock options in Aural Analytics and Nocira.
Funding Information:
This study was funded by Novartis Pharma AG, Basel, Switzerland.
Publisher Copyright:
© 2021 Novartis Pharma Italy. Published by Informa UK Limited, trading as Taylor & Francis Group.
PY - 2021
Y1 - 2021
N2 - Aims: To evaluate the healthcare resource use (HRU) and cost of lost productivity due to migraine among Italians with ≥4 monthly migraine days (MMDs), with a focus on those with ≥2 prior preventive treatment failures (TFs). Materials and methods: Data from Italian participants from the My Migraine Voice survey were used to assess migraine-related HRU and migraine’s impact on work productivity and daily activities using the Work Productivity and Activity Impairment questionnaire. The mean, annualized cost of lost productivity was estimated using the Human Capital Approach and extrapolated to employed Italian population with ≥4 MMDs to calculate the overall migraine-related indirect cost burden in Italy. Results: Data of 420 participants, enrolled between September 2017 and February 2018, were analyzed (mean age: 38.5 years, 81.2% women, 37.8% with ≥2 TF). During a 6-month period, 57.6% of participants visited general practitioners (mean visits: 4.5), 31.9% neurologists (mean visits: 2.6), and 26.4% headache specialists (mean visits: 2.8). Overall, 32.0% of participants had ≥1 emergency room visit (mean visits: 2.8) and 15.0% had ≥1 hospitalization (mean visits: 2.9) because of migraine in the past 12 months. Participants who were employed (N = 215) reported 15.5% absenteeism, 45.3% presenteeism, 53.8% overall work impairment, and 52.6% activity impairment. The mean annualized indirect cost was estimated to be €14,368. The annual indirect cost burden was estimated to be €7.6 billion for the employed Italian population with ≥4 MMDs. The impact of migraine was particularly high among the ≥2 TF subgroups on all parameters. The indirect cost was estimated to be €15,881 (€5,007 attributed to absenteeism). Conclusion: Migraine-related HRU and indirect costs are high among individuals with ≥4 MMDs (particularly those with ≥2 TF). There is a need for more effective treatments and better management of migraines to reduce the functional and economic burden among this difficult-to-treat population.
AB - Aims: To evaluate the healthcare resource use (HRU) and cost of lost productivity due to migraine among Italians with ≥4 monthly migraine days (MMDs), with a focus on those with ≥2 prior preventive treatment failures (TFs). Materials and methods: Data from Italian participants from the My Migraine Voice survey were used to assess migraine-related HRU and migraine’s impact on work productivity and daily activities using the Work Productivity and Activity Impairment questionnaire. The mean, annualized cost of lost productivity was estimated using the Human Capital Approach and extrapolated to employed Italian population with ≥4 MMDs to calculate the overall migraine-related indirect cost burden in Italy. Results: Data of 420 participants, enrolled between September 2017 and February 2018, were analyzed (mean age: 38.5 years, 81.2% women, 37.8% with ≥2 TF). During a 6-month period, 57.6% of participants visited general practitioners (mean visits: 4.5), 31.9% neurologists (mean visits: 2.6), and 26.4% headache specialists (mean visits: 2.8). Overall, 32.0% of participants had ≥1 emergency room visit (mean visits: 2.8) and 15.0% had ≥1 hospitalization (mean visits: 2.9) because of migraine in the past 12 months. Participants who were employed (N = 215) reported 15.5% absenteeism, 45.3% presenteeism, 53.8% overall work impairment, and 52.6% activity impairment. The mean annualized indirect cost was estimated to be €14,368. The annual indirect cost burden was estimated to be €7.6 billion for the employed Italian population with ≥4 MMDs. The impact of migraine was particularly high among the ≥2 TF subgroups on all parameters. The indirect cost was estimated to be €15,881 (€5,007 attributed to absenteeism). Conclusion: Migraine-related HRU and indirect costs are high among individuals with ≥4 MMDs (particularly those with ≥2 TF). There is a need for more effective treatments and better management of migraines to reduce the functional and economic burden among this difficult-to-treat population.
KW - Italy
KW - economic burden
KW - healthcare resource use
KW - indirect costs
KW - lost productivity
KW - migraine
KW - work productivity
UR - http://www.scopus.com/inward/record.url?scp=85107373941&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85107373941&partnerID=8YFLogxK
U2 - 10.1080/13696998.2021.1925557
DO - 10.1080/13696998.2021.1925557
M3 - Article
C2 - 33955821
AN - SCOPUS:85107373941
SN - 1369-6998
VL - 24
SP - 717
EP - 726
JO - Journal of Medical Economics
JF - Journal of Medical Economics
IS - 1
ER -